Market Research Logo

Atrial Fibrillation - Pipeline Review, H2 2015

Atrial Fibrillation - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Atrial Fibrillation - Pipeline Review, H2 2015’, provides an overview of the Atrial Fibrillation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Atrial Fibrillation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Atrial Fibrillation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Atrial Fibrillation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Atrial Fibrillation Overview
Therapeutics Development
Pipeline Products for Atrial Fibrillation - Overview
Pipeline Products for Atrial Fibrillation - Comparative Analysis
Atrial Fibrillation - Therapeutics under Development by Companies
Atrial Fibrillation - Therapeutics under Investigation by Universities/Institutes
Atrial Fibrillation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Atrial Fibrillation - Products under Development by Companies
Atrial Fibrillation - Products under Investigation by Universities/Institutes
Atrial Fibrillation - Companies Involved in Therapeutics Development
ARCA biopharma, Inc.
Armetheon, Inc.
AstraZeneca Plc
Bristol-Myers Squibb Company
Cardiome Pharma Corp.
Daiichi Sankyo Company, Limited
Gilead Sciences, Inc.
Isis Pharmaceuticals, Inc.
Laboratoires Pierre Fabre SA
Nissan Chemical Industries, Ltd.
Nyken BV
Otsuka Holdings Co., Ltd.
Xention Limited
Atrial Fibrillation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AT-300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-394136 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-919373 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bucindolol hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
budiodarone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F-373280 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-CRPRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NIP-151 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NYK-1112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OMT-33 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPC-108459 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranolazine ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Block Kv1.5, Nav1.5, IKACh for Atrial Fibrillation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vanoxerine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vernakalant hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEN-R0702 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEND-0103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XENR-0703 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XENR-0706 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atrial Fibrillation - Recent Pipeline Updates
Atrial Fibrillation - Dormant Projects
Atrial Fibrillation - Discontinued Products
Atrial Fibrillation - Product Development Milestones
Featured News & Press Releases
Sep 23, 2015: UK’s NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation
Sep 14, 2015: Laguna Pharmaceuticals Initiates Phase 3 Study of Vanoxerine in Atrial Fibrillation and Atrial Flutter
Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China
Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are Spoilt for Choice
Jun 25, 2015: Daiichi Sankyo’s Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE
Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation
Apr 27, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe
Apr 15, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland
Apr 09, 2015: Cardiome Receives BRINAVESS Reimbursement Approval From Belgian Authorities
Feb 09, 2015: SAVAYSA (edoxaban) Now Available in U.S. Pharmacies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Atrial Fibrillation, H2 2015
Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H2 2015
Atrial Fibrillation - Pipeline by Armetheon, Inc., H2 2015
Atrial Fibrillation - Pipeline by AstraZeneca Plc, H2 2015
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H2 2015
Atrial Fibrillation - Pipeline by Cardiome Pharma Corp., H2 2015
Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H2 2015
Atrial Fibrillation - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H2 2015
Atrial Fibrillation - Pipeline by Nyken BV, H2 2015
Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Atrial Fibrillation - Pipeline by Xention Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Atrial Fibrillation Therapeutics - Recent Pipeline Updates, H2 2015
Atrial Fibrillation - Dormant Projects, H2 2015
Atrial Fibrillation - Dormant Projects (Contd..1), H2 2015
Atrial Fibrillation - Dormant Projects (Contd..2), H2 2015
Atrial Fibrillation - Dormant Projects (Contd..3), H2 2015
Atrial Fibrillation - Discontinued Products, H2 2015
Atrial Fibrillation - Discontinued Products (Contd..1), H2 2015
List of Figures
Number of Products under Development for Atrial Fibrillation, H2 2015
Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report